Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)
China · Delayed Price · Currency is CNY 7.14
-0.17 (-2.33%)
Feb 4, 2026, 3:08 PM CST
SHE:300639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 682.35 | 806.72 | 1,075 | 5,519 | 2,647 | 1,340 |
Other Revenue | 8.81 | 8.81 | 29.75 | 78.35 | 26.43 | 14.13 |
| 691.16 | 815.53 | 1,104 | 5,597 | 2,673 | 1,354 | |
Revenue Growth (YoY) | -20.01% | -26.16% | -80.27% | 109.39% | 97.34% | 85.70% |
Cost of Revenue | 413.29 | 440.35 | 442.1 | 1,807 | 865.5 | 361.09 |
Gross Profit | 277.87 | 375.18 | 662.35 | 3,790 | 1,808 | 993.4 |
Selling, General & Admin | 434.63 | 482 | 532.48 | 847.68 | 581.7 | 445.73 |
Research & Development | 68.98 | 85.64 | 136.32 | 247.28 | 115.29 | 71.62 |
Other Operating Expenses | 14.33 | 10.81 | 9.93 | 21.3 | 12.88 | 7.33 |
Operating Expenses | 822.15 | 1,185 | 667.97 | 1,367 | 761.63 | 543.83 |
Operating Income | -544.28 | -810.23 | -5.62 | 2,424 | 1,046 | 449.57 |
Interest Expense | -3.05 | -1.58 | -4.94 | -8.18 | -7.4 | -0.8 |
Interest & Investment Income | 15.71 | 27.4 | 47.45 | 36.4 | 24.42 | 9.86 |
Currency Exchange Gain (Loss) | -20.95 | -20.95 | -15.89 | -2.36 | 0.86 | -0.31 |
Other Non Operating Income (Expenses) | 17.67 | -1.82 | -1.55 | -2.29 | -1.21 | -1.13 |
EBT Excluding Unusual Items | -534.91 | -807.19 | 19.44 | 2,447 | 1,063 | 457.19 |
Gain (Loss) on Sale of Investments | 7.26 | 4.05 | -0 | 0.04 | 0.14 | - |
Gain (Loss) on Sale of Assets | -1.34 | -0.25 | 7.06 | 4.34 | 2.34 | 5.06 |
Asset Writedown | -14.22 | -24.79 | 1.56 | -291.74 | -6.42 | -0.59 |
Other Unusual Items | -6.66 | -4.79 | 8.76 | -31.96 | -1.44 | 2.31 |
Pretax Income | -549.87 | -832.97 | 36.82 | 2,128 | 1,057 | 463.98 |
Income Tax Expense | 189.14 | 117.38 | -31.7 | 326.06 | 172.24 | 69.32 |
Earnings From Continuing Operations | -739.01 | -950.35 | 68.51 | 1,802 | 884.94 | 394.66 |
Minority Interest in Earnings | 218.37 | 295.47 | 71.96 | -75.81 | -32.78 | -31.99 |
Net Income | -520.64 | -654.88 | 140.47 | 1,726 | 852.16 | 362.66 |
Net Income to Common | -520.64 | -654.88 | 140.47 | 1,726 | 852.16 | 362.66 |
Net Income Growth | - | - | -91.86% | 102.54% | 134.97% | 146.22% |
Shares Outstanding (Basic) | 639 | 642 | 562 | 659 | 659 | 614 |
Shares Outstanding (Diluted) | 639 | 642 | 562 | 659 | 659 | 614 |
Shares Change (YoY) | 14.83% | 14.27% | -14.71% | -0.02% | 7.39% | 3.55% |
EPS (Basic) | -0.81 | -1.02 | 0.25 | 2.62 | 1.29 | 0.59 |
EPS (Diluted) | -0.81 | -1.02 | 0.25 | 2.62 | 1.29 | 0.59 |
EPS Growth | - | - | -90.46% | 102.58% | 118.80% | 137.77% |
Free Cash Flow | 89.29 | -69.55 | -65.72 | 574.85 | -9.73 | 24.18 |
Free Cash Flow Per Share | 0.14 | -0.11 | -0.12 | 0.87 | -0.01 | 0.04 |
Dividend Per Share | - | - | 0.065 | 0.233 | 0.155 | 0.089 |
Dividend Growth | - | - | -72.14% | 50.03% | 74.13% | 25.77% |
Gross Margin | 40.20% | 46.01% | 59.97% | 67.72% | 67.62% | 73.34% |
Operating Margin | -78.75% | -99.35% | -0.51% | 43.30% | 39.13% | 33.19% |
Profit Margin | -75.33% | -80.30% | 12.72% | 30.84% | 31.88% | 26.77% |
Free Cash Flow Margin | 12.92% | -8.53% | -5.95% | 10.27% | -0.36% | 1.79% |
EBITDA | -392.76 | -652.7 | 159.93 | 2,591 | 1,127 | 499.61 |
EBITDA Margin | -56.83% | -80.03% | 14.48% | 46.29% | 42.17% | 36.89% |
D&A For EBITDA | 151.52 | 157.54 | 165.55 | 167.29 | 81.33 | 50.04 |
EBIT | -544.28 | -810.23 | -5.62 | 2,424 | 1,046 | 449.57 |
EBIT Margin | -78.75% | -99.35% | -0.51% | 43.30% | 39.13% | 33.19% |
Effective Tax Rate | - | - | - | 15.32% | 16.29% | 14.94% |
Revenue as Reported | 691.16 | 815.53 | 1,104 | 5,597 | 2,673 | 1,354 |
Advertising Expenses | - | 14.31 | 24.2 | 36.3 | 29.35 | 20.11 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.